Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott’s Architect Core

This article was originally published in The Gray Sheet

Executive Summary

Firm files PMA for its automated, qualitative hepatitis B diagnostic, which detects antibodies to the hepatitis B virus core antigen. The test is run on the firm's Architect laboratory immunoassay analyzer. Abbott cites CDC statistics indicating that 1.25 million people in the U.S. have chronic hepatitis B

You may also be interested in...



Abbott HBV test

Firm gains PMA approval for its Architect Core automated hepatitis B test that runs on its Architect i2000 and Architect i2000SR immunoassay testing instruments. Abbott filed the PMA in October (1"The Gray Sheet" Oct. 6, 2008, In Brief). Architect Core is a chemiluminescent microparticle immunoassay for the qualitative detection of the IgG and IgM antibodies to the hepatitis B core antigen in blood serum and plasma. It is indicated for aiding the diagnosis of acute, chronic or resolved hepatitis B virus infection in conjunction with other laboratory results or clinical information. The Centers for Disease Control and Prevention advises individuals needing immunosuppressive therapy to be tested for the hepatitis B core antigen as well as the hepatitis B surface antigen and the antibody to HBsAg, because immunosuppressive therapy may increase the risk for reactivation in patients with resolved hepatitis B infection, according to the company

WHO To Clean Up Data Integrity Failings

The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date. 

Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

UsernamePublicRestriction

Register

MT026632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel